Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

2.IABnRgIRlYwyFHkME9yXUC2YaceEfh6Adym23S9jIIY.REI2AlJl98hccx1HSpmjNRjhMKzyH33yQ2HEj3oUWt9FbAx_UUPX-kBHLA~872548549853e04fca6c6a6a8cb281e7
05-18 BofA Securities Adjusts CONMED Price Target to $40 From $52 MT
03-17 Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55 MT
25-06-12 Conmed Shares Fall After Needham Downgrade MT
25-06-12 Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target MT
25-04-28 Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75 MT
25-02-06 JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85 MT
24-08-01 Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating MT
24-07-25 Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating MT
24-04-25 Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating MT
24-04-25 Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating MT
24-02-01 Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating MT
24-02-01 JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating MT
23-10-27 Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating MT
23-10-26 Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating MT
23-07-27 Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating MT
23-07-27 Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating MT
23-06-05 Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating MT
23-05-22 CL King Starts CONMED at Buy With $140 Price Target MT
23-04-27 Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating MT
23-04-27 Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating MT
23-04-27 Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating MT
23-04-27 Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating MT
23-03-27 CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving MT
23-03-27 Analyst recommendations: Caterpillar, Conmed, Corning, Model N, United Rentals... Zonebourse
23-02-03 Needham Raises Price Target on CONMED to $122 From $106, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +9.09%
+31.54%
+22.84%
+24.66%
+17.13%
+22.63%
+39.98%
+13.24%
+8.42%
+28.32%
Average +21.78%
Weighted average by Cap. +25.08%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
34.41USD
Average target price
39.60USD
Spread / Average Target
+15.08%
High Price Target
40.00USD
Spread / Highest target
+16.25%
Low Price Target
39.00USD
Spread / Lowest Target
+13.34%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Piper Sandler
Needham & Co.
Stifel Nicolaus
JPMorgan Chase
Wells Fargo Securities
KeyBanc Capital Markets
CL King
Jefferies & Co.
UBS
Barclays
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
34.41USD
Average target price
39.60USD
Spread / Average Target
+15.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNMD Stock
  4. Consensus CONMED Corporation
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!